Alebund Pharmaceuticals HY26 net loss narrows 22.5% to RMB 162.55 million; revenue rises to RMB 104.16 million

• Alebund posted revenue of RMB 104.16 million, up 761.2%, driven by RMB 79.3 million AP306 licensing revenue.
• Net loss narrowed 22.5% to RMB 162.55 million; basic loss per share improved to RMB 0.57.
• Gross profit rose to RMB 91.09 million; gross margin expanded to 87.5% from 43.4%.
• R&D expenses increased 28.4% to RMB 141.4 million as AP301 Phase III MRCT enrollment completed and AP306 Phase IIb began.
• Mircera revenue more than doubled to RMB 24.8 million; AP301 China NDA was accepted for NMPA review on Aug. 7, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals (Jiangsu) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300193), on August 26, 2026, and is solely responsible for the information contained therein.